Acquisition of U.S. Generics Company by Indian Pharmaceutical Manufacturer
Kegler Brown Hill + Ritter served as buy-side counsel for India-based Strides Pharma, Inc., in its acquisition of U.S.-based generics company Vensun Pharmaceuticals, Inc., represented by Goodwin Procter LLP.
Strides benefits from Vensun’s strategic focus on niche ANDAs, and its portfolio of 16 commercialized ANDAs, four of which are partnered with Strides and constitute a significant part of Vensun’s current revenues of $~17 million.
Vensun’s portfolio also comprises an additional 13 filed ANDAs, which includes Strides Competitive Generic Therapy (CGT) designated product with a $400 million market opportunity. The company also has a development pipeline with two other partners for ten products.